Semaglutide vs. Tirzepatide vs. Compounded: What the Data Actually Shows is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
A friend of mine, a nurse practitioner named Dana who runs a metabolic health clinic outside Austin, told me something last fall that stuck with me. She’d had three patients in the same week come in with printouts from three different telehealth companies, each claiming their GLP-1 option was “the best.” One was pushing branded Zepbound. Another was selling compounded semaglutide. The third had a slick comparison chart that was technically accurate but arranged to make their product look superior. Dana’s reaction: “Everyone’s selling a winner. Nobody’s explaining the tradeoffs.”
That’s the problem with how most of this content gets written. The molecules are real. The data is solid. But the framing is almost always pointed toward whatever the company behind the page happens to sell. So here’s an attempt at the version Dana wishes her patients would read before their appointments.
The pharmacology, minus the jargon
Semaglutide (the molecule behind Ozempic and Wegovy) is a GLP-1 receptor agonist with a half-life of about seven days, which is why it works as a weekly injection. It mimics a gut hormone that tells your brain you’re full and slows how fast food leaves your stomach.
Tirzepatide (the molecule behind Mounjaro and Zepbound) does the same thing but adds a second receptor target: GIP. That dual action is what makes it pharmacologically distinct. Think of semaglutide as a single-channel radio and tirzepatide as dual-band. Both play music; one picks up more stations.
Now, the numbers. The STEP-1 trial (Wilding et al., NEJM 2021) showed semaglutide 2.4 mg produced 14.9% mean body weight loss over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed tirzepatide at its three dose tiers produced mean reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) over 72 weeks. SURMOUNT-5, presented in 2024, put them head-to-head and confirmed tirzepatide’s edge in mean weight reduction over 72 weeks.
Tirzepatide wins on averages. But averages obscure a wide individual spread. Some people lose 25% of their body weight on semaglutide. Some lose 8% on high-dose tirzepatide. The population-level superiority is real; the individual prediction is messy.
Branded vs. compounded: the actual differences
Here’s where the conversation gets noisy, and where I think most patient-facing content fails.
The active ingredient in compounded tirzepatide is tirzepatide. Same molecule. The differences are in manufacturing, regulatory oversight, packaging, and price. Those differences matter, but they’re not the same as saying the drug itself is different.
Branded Zepbound and Mounjaro are FDA-approved finished drugs made by Eli Lilly under cGMP (current Good Manufacturing Practice) standards. They carry established labeling, post-marketing surveillance, and all the quality controls that come with being a commercially manufactured pharmaceutical product.
Compounded preparations come from 503A pharmacies (patient-specific prescriptions, state-regulated) or 503B outsourcing facilities (inspected under federal standards, allowed to produce office stock). They are not FDA-evaluated for safety, efficacy, or quality the way branded drugs are. The regulatory framework relies on state pharmacy boards, federal 503A/503B requirements, and the clinical judgment of the prescribing clinician.
The honest version of “which is better?” is: branded products carry stronger regulatory assurance. Compounded products cost less and sometimes allow more flexible dosing. Which one is appropriate depends on your clinical situation, your insurance, and whether you have access to a prescriber who’s actually supervising your care (not just rubber-stamping a form).
Patients evaluating compounded options should look at pharmacy credentialing (state licensure, third-party accreditation where applicable), the quality of clinical oversight (a real evaluation, not a checkbox questionnaire), and transparent pricing. For a deeper breakdown of how these categories compare, this resource covers the regulatory and dosing specifics in more detail.
The titration schedule nobody reads closely enough
Standard tirzepatide dosing starts at 2.5 mg weekly for four weeks. This is the tolerance phase. It is not the therapeutic phase. Most people lose little or nothing here, and the ones who panic about it being “not working” are usually just on track.
At week five, you step to 5 mg. This is where real appetite suppression typically kicks in. From there, the protocol moves through 7.5, 10, 12.5, and up to 15 mg at four-week intervals, based on tolerance and response.
| Phase | Dose | Duration | What’s actually happening | |—|—|—|—| | Initiation | 2.5 mg weekly | Weeks 1-4 | GI tolerance building, minimal weight loss expected | | Step 1 | 5 mg weekly | Weeks 5-8 | First real appetite suppression for most patients | | Step 2 | 7.5 mg weekly | Weeks 9-12 | Some prescribers hold here if response is adequate | | Step 3 | 10 mg weekly | Weeks 13-16 | Common long-term maintenance tier | | Step 4 | 12.5 mg weekly | Weeks 17-20 | For patients with attenuating response | | Step 5 | 15 mg weekly | Week 21+ | Maximum labeled dose; not everyone needs it |
Not every patient needs to hit 15 mg. Many stabilize between 5 and 10 mg once they’ve reached a goal weight, balancing ongoing benefit against side effects and cost. One practical advantage of compounded preparations is the availability of intermediate doses (6.25 mg, 8.75 mg) that aren’t offered in branded autoinjectors. When someone is struggling right at the threshold of a dose step, that granularity can matter.
Side effects: the boring truth
Nausea is the headline. Thirty to 45% of patients in trial populations reported it. But “reported nausea” covers everything from mild queasiness after a big meal to can’t-get-off-the-couch misery. Most side effects cluster in the first four to eight weeks and around dose escalations, peaking shortly after a step-up and fading within two to three weeks at a stable dose.
| Symptom | Frequency | Timing | Management | |—|—|—|—| | Nausea | 30-45% | First 4-8 weeks, dose escalations | Smaller meals, lower fat intake, antiemetic if persistent | | Diarrhea | 15-23% | Variable | Hydration, electrolyte monitoring, bland diet temporarily | | Constipation | 10-17% | After gastric slowing takes hold | Fiber (25-35g daily), hydration, magnesium if clinician approves | | Vomiting | 8-13% | First weeks and escalations | Hold dose, contact prescriber if it persists | | Reflux | 7-12% | Throughout therapy | No eating within 3 hours of bedtime, raise head of bed | | Fatigue | Variable | First weeks | Usually self-resolving; check ferritin, B12, thyroid if it lingers |
The serious risks deserve a separate paragraph because people skim tables. Labeled warnings include pancreatitis, gallbladder disease, severe hypoglycemia (especially combined with insulin or sulfonylureas), kidney injury from dehydration, and a boxed warning for medullary thyroid carcinoma based on rodent data.
Baseline labs before starting: comprehensive metabolic panel, HbA1c and fasting glucose, lipid panel, TSH, lipase (especially if there’s any personal history of pancreatitis), and CBC. Recheck at 12 to 16 weeks, then roughly every six months once stable. Severe abdominal pain radiating to the back warrants immediate clinician contact to rule out pancreatitis. Not “call on Monday.” Now.
How people actually decide
In practice, the decision tree looks something like this:
Diabetes status shapes the branded option. Mounjaro and Ozempic carry type 2 diabetes indications; Zepbound and Wegovy are labeled for chronic weight management.
Insurance and cost drive more decisions than anyone in medicine likes to admit. Patients with strong coverage typically use branded. Cash-pay patients without coverage gravitate toward compounded options because the price difference can be several hundred dollars a month.
Prior experience with GLP-1s matters a lot. Someone who tolerated semaglutide well but plateaued might move to tirzepatide for the additional weight loss potential. Someone who had bad GI reactions on one molecule needs a careful conversation before trying the other, because the GLP-1-mediated side effects overlap significantly.
Adherence realism. I think this is the most underrated factor. The best molecule on paper is worthless if someone stops taking it at week six because the side effects weren’t managed or the cost wasn’t sustainable. Theoretical efficacy without adherence doesn’t produce outcomes.
When to call your clinician (and how urgently)
Immediately: severe abdominal pain (especially radiating to the back), signs of significant dehydration, vision changes in diabetic patients, signs of allergic reaction.
Within a few days: side effects that substantially limit daily function, vomiting persisting beyond 48 hours, reflux that doesn’t respond to timing and positioning changes.
At your next routine visit: dose pacing questions, weight loss plateau review, lab monitoring schedule, long-term planning.
A licensed clinician should be involved in any decision to start, adjust, or stop therapy. That’s not a legal disclaimer. It’s how people avoid problems.
Frequently asked questions
Is tirzepatide more effective than semaglutide?
On a population level, yes. SURMOUNT-5 head-to-head data showed tirzepatide producing greater mean weight loss than semaglutide over 72 weeks. But individual response varies considerably, and the right choice depends on tolerability, cost, access, and clinical history.
What’s the actual pharmacological difference between the two?
Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). The dual receptor activity likely contributes to the greater mean weight loss observed in trials, though the exact contribution of GIP agonism is still being studied.
Can I switch from one to the other?
Yes, under clinician guidance. The standard approach is to start the new molecule at its beginning dose rather than trying to match the prior dose, then re-titrate. This helps assess tolerance to the new agent.
Which one has worse side effects?
Both share GLP-1-driven GI side effects: nausea, constipation, diarrhea. Reported rates in clinical trials are broadly similar. Individual variation matters more than population averages here.
Is branded automatically better than compounded?
Branded products carry FDA manufacturing oversight, established labeling, and post-marketing surveillance. Compounded preparations are not FDA-approved. “Better” isn’t the right framing. The question is which option is appropriate given your clinical context, financial situation, and access to proper oversight.
How do I decide which to start?
Talk to a clinician who will review your full history. The decision typically weighs diabetes status, BMI, prior medication experience, side effect sensitivity, cost, and logistical access.
Important regulatory note. Compounded tirzepatide is not FDA-approved. It is prepared by licensed 503A or 503B pharmacies for individual patients based on a prescriber’s clinical judgment. Compounded preparations are not evaluated by the FDA for safety, efficacy, or quality the way branded products are. Research suggests outcomes vary between patients, and any decision to begin, modify, or discontinue therapy should occur in coordination with a licensed clinician who can review your medical history, current medications, and laboratory values.
